National Quality Indicator – Prevalence of Inhibitors

Decrease the prevalence of inhibitors in active patients with hemophilia A.

Data Source: ATHNdataset

2014 Baseline – Active Inhibitor: 6.8%
2016 Most Recent Result - Active Inhibitor: 6.0%

2014 Baseline – History of Inhibitor: 5.3%
2016 Most Recent Result – History of Inhibitor: 8.36%

Calculation of Active Inhibitors: 
Numerator: Number of active patients with hemophilia who had an inhibitor in a specific 12-month period.
Denominator: Number of active patients with hemophilia in the specific 12-month period.

Calculation of History of Inhibitors:
Numerator: Number of active patients with hemophilia who have a past history of or an inactive inhibitor during a specific time interval.
Denominator: Number of active patients with hemophilia during the specific time interval.

2016 Conclusion:
The prevalence of active hemophilia patients with an active inhibitor was 5.1% in 2016.